Voro Therapeutics to Present New Preclinical Data on PrimeBody™ Platform and VOR-101 at Upcoming AACR 2026 and AET Europe Conferences
Voro Therapeutics announced upcoming oral presentations at AACR Annual Meeting 2026 and AET Europe, where it will showcase new preclinical data on its PrimeBody biologics platform and lead program VOR-101.
Voro Therapeutics will present new preclinical PrimeBody and VOR-101 data at AACR 2026 and AET Europe, highlighting tumor-activated biologics and therapeutic potential.
Key facts
- Voro Therapeutics will give oral presentations at AACR Annual Meeting 2026 and AET Europe.
- The company will present new preclinical data on its proprietary PrimeBody™ platform and lead program VOR-101.
- The data are designed to show tumor-selective activation and a broad therapeutic index.
- Voro will also highlight broader applications in T-cell engagers, antibody-drug conjugates, and cytokines.
SAN DIEGO — Voro Therapeutics, a biotechnology company pioneering tumor-activated biologics to improve the safety and efficacy of cancer therapies, today announced upcoming oral presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 and the Antibody Engineering & Therapeutics (AET) Europe conference.
Voro Therapeutics will present new preclinical data showcasing the power of its proprietary PrimeBody biologics platform and the broad therapeutic index of its lead program, VOR-101. The presentations will demonstrate how PrimeBody’s novel protease-cleavable linkers and affinity-tuned masking domains drive tumor-selective activation, enabling the safe and effective deployment of highly potent warheads that are not achievable with conventional approaches.
Voro will also highlight the platform’s broader potential through applications in T-cell engagers, antibody-drug conjugates and cytokines. Taken together, the upcoming conference appearances are intended to show that PrimeBody is not limited to a single product concept, but may have broad applicability across multiple biologic modalities in oncology drug development.
Presentation details for AACR 2026 and AET Europe
Presentation Details
American Association for Cancer Research (AACR) Annual Meeting 2026
San Diego Convention Center • San Diego, CA • April 17–22, 2026
Date: April 20, 2026
Session: MS.IM01.02 - Advances in Therapeutic Antibodies
Title: Tumor-Activated PrimeBody Biologics Platform Enables More Potent CD47 Targeting and Superior Therapeutic Index in Preclinical Models
Presenter: Aaron Springer, PhD, Associate Director of Preclinical Biology, Voro Therapeutics
Antibody Engineering & Therapeutics (AET) Europe
Congress Center Basel • Basel, Switzerland • May 27–29, 2026
Date: May 29, 2026
Session: Masked, Gated, Conditionally Activated Antibodies
Title: Tumor-Activated PrimeBody Platform Unlocks the Safe and Effective Delivery of Potent Biologics Beyond the Reach of Conventional Approaches
Presenter: Ugur Eskiocak, PhD, Co-Founder and CEO, Voro Therapeutics
PrimeBody platform aims to improve safety and efficacy of cancer therapies
According to the company, the PrimeBody platform is designed to keep therapeutics masked in healthy tissues and in systemic circulation, while selectively activating them within the tumor microenvironment. This approach is meant to improve the safety and efficacy of cancer therapies by reducing off-tumor activity and enabling more precise tumor targeting.
The preclinical data to be presented are expected to demonstrate how protease-cleavable linkers and affinity-tuned masking domains can support tumor-selective activation. Voro says this design could allow highly potent warheads to be delivered more safely and effectively than with conventional approaches, a concept that may be especially important in difficult oncology targets where toxicity has traditionally limited development.
The company will use the upcoming AACR 2026 and AET Europe presentations to underscore both the strength of its PrimeBody™ platform and the therapeutic potential of VOR-101 in preclinical oncology models.
VOR-101 and broader applications across biologic modalities
Beyond VOR-101, Voro Therapeutics plans to highlight broader platform potential across T-cell engagers, antibody-drug conjugates and cytokines. That positioning is important because it suggests PrimeBody may serve as a foundation technology rather than a single-asset strategy, with possible application across several classes of tumor-activated biologics.
This broader applicability could help differentiate Voro in the oncology biotechnology space, where companies increasingly seek platform-based approaches that can generate multiple product candidates across different targets and mechanisms. By framing PrimeBody as a tool for safer and more effective delivery of potent biologics, Voro is emphasizing both platform scalability and translational relevance.
About Voro Therapeutics
Voro Therapeutics is a privately held biotechnology company pioneering tumor-activated biologics to enable safer and more effective cancer therapies. The company’s proprietary PrimeBody™ platform engineers therapeutics that remain masked in healthy tissues and systemic circulation, and selectively activate within the tumor microenvironment.
The PrimeBody platform is designed for broad applicability across diverse biologic modalities, including antibody-drug conjugates (ADCs), T-cell engagers, and cytokines. Voro Therapeutics is headquartered in San Diego, California. With the upcoming presentations at AACR 2026 and AET Europe, the company is set to provide a closer look at how its platform and lead program VOR-101 may contribute to the future development of safer and more effective oncology treatments.
